Phoenux Information

Business purpose is the development of new medications for the drug substitution market. Private investors made research and development in this sector possible and successful. Since spring of 2006, Dr. Lars Hermann is the scientific head of the company. Dr. Hermann had been working as a medical doctor in this indication. Patients and authorities are desiring a new substitution medication, meeting their needs. Dr. Hermann experienced this indication as a promising market for a new medication. In Europe, 650.000 patients are receiving a once-daily substitution medication for heroin dependency. Only few medications are available. Therefore, new medications are in high demand from many sides. Phoenux AG wants to offer the patients a reliable medication. The patients should be respected and their needs accepted. Until now this patient group was often neglected. Their disease is still today often regarded as a deficiency of character. The new medication was developed based on the needs of the patients. The anti-abuse system as well as the galenic formulation were developed in extensive optimization and carefully executed studies with high scientific claim. Picture